These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 23063578

  • 1. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
    Vogelzang NJ, Bhor M, Liu Z, Dhanda R, Hutson TE.
    Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
    [Abstract] [Full Text] [Related]

  • 2. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK.
    Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R, Boni JP, Ravaud A.
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
    Buchler T, Bortlicek Z, Poprach A, Kubackova K, Kiss I, Zemanova M, Fiala O, Dusek L, Vyzula R, Melichar B, Czech Renal Cancer Cooperative Group.
    Urol Oncol; 2014 Jul; 32(5):569-75. PubMed ID: 24629497
    [Abstract] [Full Text] [Related]

  • 7. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ, Hackshaw MD, Hutson TE, Bhowmik D, Yap M, Rembert D, Jonasch E.
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [Abstract] [Full Text] [Related]

  • 8. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ.
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [Abstract] [Full Text] [Related]

  • 9. [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
    Büchler T, Dusek L, Fínek J, Poprach A, Budnáková D, Kandrnal V, Jarkovský J, Bortlícek Z, Klimes D, Abrahámová J, Vyzula R.
    Klin Onkol; 2011 Mar; 24(5):389-92. PubMed ID: 22070021
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L, Maute L, Guschmann M.
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [Abstract] [Full Text] [Related]

  • 12. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
    Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N.
    Clin Genitourin Cancer; 2016 Apr; 14(2):153-9. PubMed ID: 26781820
    [Abstract] [Full Text] [Related]

  • 13. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I, REACT Study Group.
    Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC, Barbeau S, McMillian A, Srinivas S.
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [Abstract] [Full Text] [Related]

  • 15. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial.
    N Engl J Med; 2007 May 31; 356(22):2271-81. PubMed ID: 17538086
    [Abstract] [Full Text] [Related]

  • 16. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A, Medioni J, Scotte F, Schmidinger M, Kramer G, Combe P, Gornadha Y, Elaidi R, Oudard S.
    Oncology; 2013 May 31; 85(1):8-13. PubMed ID: 23797151
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
    Mihajlović J, Pechlivanoglou P, Sabo A, Tomić Z, Postma MJ.
    Clin Ther; 2013 Dec 31; 35(12):1909-22. PubMed ID: 24238790
    [Abstract] [Full Text] [Related]

  • 18. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
    Nozawa M, Ohzeki T, Tamada S, Hongo F, Anai S, Fujimoto K, Miki T, Nakatani T, Fukasawa S, Uemura H.
    Int J Clin Oncol; 2015 Aug 31; 20(4):790-5. PubMed ID: 25342378
    [Abstract] [Full Text] [Related]

  • 19. mTOR pathway inhibition in renal cell carcinoma.
    Pinto Marín A, Redondo Sánchez A, Espinosa Arranz E, Zamora Auñón P, Castelo Fernández B, González Barón M.
    Urol Oncol; 2012 Aug 31; 30(4):356-61. PubMed ID: 20207176
    [Abstract] [Full Text] [Related]

  • 20. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
    Alimohamed N, Lee JL, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Tantravahi S, Kollmannsberger C, North S, Rini BI, Choueiri TK, Heng DY.
    Clin Genitourin Cancer; 2014 Aug 31; 12(4):e127-31. PubMed ID: 24485801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.